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Abstract
Objective
To determine the expression profile of microRNAs in the peripheral blood of pregnant
women with preterm premature rupture of membranes (PPROM) compared to that of
healthy pregnant women.
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Study design
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This was a pilot study with case-control design in pregnant patients enrolled between January 2017 and June 2019. Patients with healthy pregnancies and those affected by PPROM
between 20- and 33+6 weeks of gestation were matched by gestational age and selected
for inclusion to the study. Patients were excluded for multiple gestation and presence of a
major obstetrical complication such as preeclampsia, diabetes, fetal growth restriction and
stillbirth. A total of ten (n = 10) controls and ten (n = 10) patients with PPROM were enrolled
in the study. Specimens were obtained before administration of betamethasone or intravenous antibiotics. MicroRNA expression was analyzed for 800 microRNAs in each sample
using the NanoString nCounter Expression Assay. Differential expression was calculated
after normalization and log2- transformation using the false discovery rate (FDR) method at
an alpha level of 5%.
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Results
Demographic characteristics were similar between the two groups. Of the 800 miRNAs analyzed, 116 were differentially expressed after normalization. However, only four reached
FDR-adjusted statistical significance. Pregnancies affected by PPROM were characterized

PLOS ONE | https://doi.org/10.1371/journal.pone.0277098 November 3, 2022

1 / 12

PLOS ONE

Funding: The author(s) received no specific
funding for this work.
Competing interests: The authors have declared
that no competing interests exist.

MicroRNA analysis in premature rupture of membranes

by upregulation of miR-199a-5p, miR-130a-3p and miR-26a-5p and downregulation of miR513b-5p (FDR adjusted p-values <0.05). The differentially expressed microRNAs participate
in pathways associated with altered collagen and matrix metalloprotease expression in the
extracellular matrix.

Conclusion
Patients with PPROM have a distinct peripheral blood microRNA profile compared to
healthy pregnancies as measured by the NanoString Expression Assay.

Introduction
Premature rupture of membranes (PROM) is defined as rupture of the fetal membranes prior
to the onset of labor and can occur at any gestational age, even as late as 42 weeks of gestation.
Preterm PROM (PPROM) is defined as rupture of membranes prior to 37 weeks and complicates 2–4% of all singletons, and 7–20% of twin pregnancies. It is the most prevalent identifiable cause of preterm birth and responsible for 18–20% of perinatal deaths in the United States
[1]. PPROM is a disease of the fetal membranes characterized by proteolysis, specifically
directed to dismantle the structural integrity of the extracellular matrix (ECM) between the
amnion and chorion, weakening the membranes.
Non-coding RNAs is a wide category of small and average size RNA molecules ranging
from 22 nucleotides for microRNA to >200 nucleotides for long non-coding RNAs (lncRNA).
MicroRNAs (miRNAs) are highly conserved, single-stranded non-coding RNA molecules
that regulate gene expression at the post-transcriptional level. More than 3,000 miRNA molecules are known thus far, and each of them can potentially target more than a hundred messenger RNA molecules. While a few miRNAs are specific to different tissues and organs, they
are usually expressed in different combinations across diverse organs [2–6]. MiRNAs have a
vast potential for regulation of cellular processes and are involved in cell differentiation, proliferation, apoptosis, metabolic homeostasis, as well as pathological processes such as infections
[7], cardiovascular disease [8], and cancer [9–13]. Organ- or disease-specific miRNA expression patterns constitute miRNA profiles that may be used as diagnostic or prognostic clinical
tools.
Studies have shown that miRNAs released into the circulation exist in a very stable form in
contrast to messenger RNA molecules. Some miRNAs are released to the plasma within exosomes, which are circulating microparticles (50–100 nM in size) of endocytic origin which
could facilitate intercellular communication. Exosomes from different cell types stimulate the
immune system and have antitumorigenic effects. In contrast, exosomes released by tumor
cells can suppress the immune system and enhance tumor progression [14–19].
Exosomes are also produced in the human placenta and have been shown to help in the
establishment of maternal immune tolerance [20, 21]. Specific types of miRNAs are found in
the plasma of pregnant women, with the plasma level of selected miRNA species altered
depending on the gestational age. These observations support the role of miRNAs as extracellular messengers.
MiRNAs have also been investigated as possible biomarkers to identify women at risk for
specific obstetrical outcomes including preeclampsia. Several miRNA subtypes have been
identified to be significantly elevated in preeclampsia and gestational hypertension [22, 23].
Other studies have shown that specific profiles are present in ectopic pregnancy [24].
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Our objective was to determine whether patients with PPROM have a unique serum
miRNA profile compared to pregnancies without PPROM.

Materials and methods
We performed a case-control pilot study between healthy pregnant patients (controls) and
pregnant patients with PPROM (cases) between 20- and 33+6-weeks gestational age. Cases
and controls were matched for gestational age. Our study was approved by the institutional
review board of MedStar Health Research Institute (protocol# 2016–148). Patients with
uncomplicated singleton pregnancies were recruited by trained physicians from either the
low-risk obstetrics clinic or the midwifery clinic between January 2017 and June 2019. Patients
with PPROM were recruited at the time of admission to the hospital. All patients in that group
received betamethasone for fetal lung maturity and latency antibiotics according to hospital
protocol. The diagnosis of PPROM was made by the attending physician at the time of admission and management during the hospital course was determined by the attending physician
based on the PPROM protocol of our institution. After informed consent at the time of enrollment was obtained, specimen collection occurred at the time of initial blood draw after admission to the hospital for PPROM and before administration of betamethasone and latency
antibiotics.
Patients were excluded for multiple gestation, stillbirth, fetal growth restriction (FGR), preeclampsia, major fetal anomalies, pregestational or gestational diabetes, chronic steroid use,
acute or chronic immunologic disease, acute febrile illness at the time of presentation, cervical
incompetence/cerclage in place, and inability or unwillingness of individual or legal guardian/
representative to give written informed consent. A total of ten (n = 10) controls and ten
(n = 10) patients with PPROM were enrolled in the study. Maternal blood was processed in
order to obtain serum. All specimens were blinded to the lab performing the miRNA
quantification.

Statistical analysis
Statistical significance for baseline demographic variable associations with PPROM was determined with Chi-Square and Fisher’s exact tests for categorical variables. Continuous variable
associations with PPROM were assessed with the use of Mann-Whitney test. A p-value
of < 0.05 was considered statistically significant.

Specimen processing and total RNA isolation
Blood samples were drawn from our patients on admission to the hospital, serum was isolated
by centrifugation (1600g, 15 minutes at 4˚C) from whole blood in less than 4 hours after collection and frozen immediately at -80 ˚C. Samples were checked for the presence of small clots
and hemolysis. Specimens were maintained frozen for the duration of the study period and
were shipped from Washington Hospital Center (Washington, DC, USA) directly to Georgetown University Department of Physiology (Washington, DC, USA) on dry ice where they
remained blinded as to clinical outcome through testing, identified only by a unique identification number. MiRNA was isolated from serum samples using the miRNeasy Serum/Plasma
Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions.

Nanostring analysis
MiRNA content and expression was analyzed for 800 human miRNAs on PPROM (n = 10)
and control (n = 10) samples with the use of the NanoString nCounter miRNA/lncRNA
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Expression Assay (NanoString Technologies Inc., Seattle, WA, USA) according to manufacturer’s protocol. Sample preparation involves a multiplexed annealing of the specific tags to their
target miRNA, a ligation reaction, and an enzymatic purification to remove the unligated tags.
Sequence specificity between each miRNA and its appropriate tag is ensured by careful, stepwise control of annealing and ligation temperatures. Control RNA is included in the nCounter
Human miRNA Sample Preparation Kit.
The nCounter miRNA expression assay is run on the nCounter Analysis system. The system is comprised of two instruments, the Prep Station used for post- hybridization processing,
and the Digital Analyzer used for data collection. Data Collection is carried out in the nCounter Digital Analyzer. Digital images are processed, and the barcode counts are tabulated in a
comma separated value (CSV) format. Statistical analysis was performed with the nSolver software, v4.0 (Nanostring Technologies, Seattle, WA). Raw counts were normalized using internal positive controls as well as housekeeping genes provided in the codeset as described in the
nCounter gene expression data analysis guidelines [http://www.nanostring.com/applications/
miRNA]. Background noise was assessed using negative control probes designed not to
hybridize to any human target provided in the codeset. After normalization, log2-transformation and analysis, raw p-values for all miRNAs were corrected for multiple testing by the Benjamini–Hochberg false discovery rate [FDR] method at an alpha level of 5%. Only miRNAs
with an FDR adjusted p-value of <0.05 were considered significantly altered.

Bioinformatic miRNA target prediction
Predicted targets for the differentially expressed miRNAs were identified using the miRTargetLink version 2.0 software tool [25]. Gene Ontology [GO] and Kyoto Encyclopedia of Genes
and Genomes [KEGG] pathway analyses were performed using the mirWalk 2.0 tool [http://
www.ma.uniheidelberg.de/apps/zmf/mirwalk/] [26]. An interaction network for the differentially expressed miRNAs was created with use of strong validated targets from miRTarBase.
We used miRPathDB version 2.0 to predict biological process pathways targeted by the differentially expressed miRNAs [27].

Results
Demographic characteristics
There were no statistically significant differences in the maternal age, race, BMI, parity, mode
of delivery, umbilical cord pH and WBC count on admission between cases and controls
(Table 1). The gestational age at blood draw was not significantly different between the two
groups since patients were matched for this variable. There was a statistically significant difference in the gestational age at delivery for PPROM vs controls (29.3wks vs 39.4 wks, p<0.01),
birth weight (1345 gms vs 3246 gms, p<0.01) and 1-minute Apgar scores (5.5 vs 8.3, p<0.01).
In the PPROM group, 4 patients (40%) had a history of preterm delivery compared with no
patients in the control group having such history. Three patients in the PPROM group (30%)
went into spontaneous labor while two (20%) were induced. Indications for c-section in the
PPROM group included placenta previa (10%), malpresentation (30%) and chorioamnionitis
with non-reassuring fetal heart rate pattern (10%).

Differential expression of miRNAs between PPROM and controls
Of the 800 miRNAs analyzed on the array, 116 showed differential expression between
PPROM and control subjects with a statistical significance of <0.05 after normalization. However, only 4 miRNAs were significantly over- or under-expressed based on an FDR-adjusted
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Table 1. Demographic characteristics.
Controls (n = 10)

PPROM (n = 10)

Age (years)

32.5±4.8

30.4±6.6

p-value
0.455

BMI

26.8±4.8

28.9±6.7

0.45

Race

0.851

African-American (%)

60

Other (%)

40

80
20

GA at collection (wks)

28.3±4.4

28.5±4.5

0.93

GA at delivery (wks)

39.4±1.3

29.2±4.5

<0.01

Nulliparous (%)

40

30

SVD (%)

80

50

Cesarean section (%)

20

50

0.32

Mode of delivery

0.175

Birth weight (gms)

3246.2±561

1345.2±641

<0.01

Apgar 1 min

8.3±1.1

5.5±2.9

<0.01

Apgar 5 min

8.8±0.6

6.6±3.1

0.055

Cord pH

7.25±0.04

7.26±0.08

0.793

WBC count (admission)

9.28±2.9

9.8±2.7

0.705

Values given as average ± standard deviation
BMI = body mass index, GA = gestational age, SVD = spontaneous vaginal delivery, WBC = white blood cell count
https://doi.org/10.1371/journal.pone.0277098.t001

p-value of <0.05 (Table 2). Three of the miRNAs (miR-513b-5p, miR-199a-5p and miR-130a3p) had a >2-fold change in expression between PPROM and controls while one (miR-26a5p) had a 1.86-fold change. miR-513b-5p was the only target to be significantly underexpressed in PPROM patients, while the other three were overexpressed. The remainder of
miRNAs had an FDR-adjusted p-value of �0.05. Two additional miRNAs, miR-516b-5p and
miR-526a, known to be part of the C19MC cluster on chromosome 19, expressed exclusively
in the placenta, were under-expressed in the serum of PPROM patients (p-values of 0.004 and
0.006 respectively) but the FDR-adjusted p-value did not reach statistical significance (p = 0.33
and 0.43 respectively). The top 25 differentially expressed miRNAs based on FDR-adjusted pvalue are shown on Table 3. Heatmaps of miRNA expression for all 800 targets and the top 25
differentially expressed miRNAs are shown in Figs 1 and 2 respectively.
Pathways putatively targeted by the 4 microRNAs. We used miRTargetlink 2.0 [25] to
identify putative target pathways and genes for the four differentially expressed miRNAs that
reached statistical significance. The top 20 significant biological process pathways for the network identified by miRPathDB 2.0 [27] are shown on Fig 3. Those with the highest statistical
significance regulate the SMAD protein signal transduction pathway and the pathwayrestricted SMAD protein phosphorylation. Regulation of T cell chemotaxis also appears to be a
Table 2. MiRNAs with FDR adjusted p-value <0.05.
MicroRNA

Fold change

miR-26a-5p
miR-513b-5p

1.86
-2.4

p-value

FDR adjusted p-value

0.00006

0.01

0.0001

0.02

miR-199a-5p

2.31

0.0003

0.03

miR-130a-3p

2.64

0.0005

0.03

FDR = false discovery rate
https://doi.org/10.1371/journal.pone.0277098.t002
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Table 3. Top 25 differentially expressed miRNAs.
MicroRNA

Fold change

hsa-miR-26a-5p
hsa-miR-513b-5p
hsa-miR-199a-5p
hsa-miR-130a-3p

1.86

p-value

FDR adjusted p-value

0.00006473

0.01

0.00016399

0.02

2.31

0.00034716

0.03

2.64

-2.4

0.00035399

0.03

hsa-miR-30e-5p

-1.6

0.00052207

0.05

hsa-miR-154-5p

-2.07

0.00070497

0.06

hsa-let-7d-5p

3.49

0.00085758

0.08

hsa-miR-630

-2.76

0.00123896

0.11

hsa-miR-30c-5p

-2.44

0.00133779

0.11

hsa-let-7g-5p

1.94

0.00193919

0.16

hsa-miR-126-3p

3.02

0.0021172

0.18

hsa-miR-129-5p

-3.03

0.00222641

0.18

hsa-miR-199a-3p/hsa-miR-199b-3p

2.77

0.00324963

0.26

hsa-miR-125a-5p

2.17

0.00330485

0.26

10.31

0.00342399

0.27

0.003756

0.29

hsa-let-7a-5p
hsa-miR-374b-5p

1.65

hsa-miR-516b-5p

-1.85

0.00427739

0.33

hsa-miR-151a-3p

1.96

0.00455393

0.34

hsa-miR-208b-5p

-1.96

0.00459024

0.34

1.75

0.00472435

0.35

0.00488638

0.36

hsa-miR-107
hsa-miR-491-5p

-2.4

hsa-miR-191-5p

2.48

0.00501527

0.36

hsa-miR-323b-3p

-1.95

0.00593652

0.42

hsa-miR-526a

-1.89

0.00616295

0.43

https://doi.org/10.1371/journal.pone.0277098.t003

common pathway targeted by three of the index miRNAs. The interaction graph is shown in
Fig 4. Molecular functions affected by the upregulated miRNAs were also identified and
include protein kinase activity, nitric-oxide synthase activity and promoter sequence-specific
DNA binding as shown in Fig 5.
Target pathways for miR-513b-5p do not appear to overlap with the remainder of the interaction network and include regulation of DNA-binding transcription factor activity as well as

Fig 1. Heatmap of miRNA expression in PPROM and control group for all 800 targets with color key.
https://doi.org/10.1371/journal.pone.0277098.g001
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Fig 2. Heatmap of miRNA expression for the top 25 differentially expressed miRNAs with color key.
https://doi.org/10.1371/journal.pone.0277098.g002

RNA biosynthesis. However, miR-513b-5p was recently shown to directly target Collagen type
I alpha 1 chain (COL1A1) and COL1A2 to inhibit matrix metalloproteinase (MMP) pathways,
thereby enhancing vascular smooth muscle cell death, apoptosis, inflammation and extracellular matrix destruction [28].

Comment
Principal findings. The results of our study suggest that pregnancies affected by PPROM
have a distinct serum miRNA profile that is characterized by upregulation of miR-199a-5p,
miR-130a-3p and miR-26a-5p and downregulation of miR-513b-5p. In addition, placentaderived miR-516b-5p and miR-526a were downregulated in PPROM vs controls but the foldchange did not reach FDR-adjusted statistical significance.
Results in the context of what is known. To our knowledge this is the first study to investigate miRNA expression in the serum of patients with PPROM. MiRNAs are known to target
many genes through complex regulatory networks whose function remains to be elucidated.
Downregulation of miR-513b-5p provided one of the strongest signals in our study. Interestingly, Zheng et al. [28] recently demonstrated that serum levels of miR-513b-5p were significantly decreased in patients with ruptured intracranial aneurysms compared to controls.

Fig 3. miRPathDB predicted biological process pathways for target miRNAs.
https://doi.org/10.1371/journal.pone.0277098.g003
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COL1A1 and COL1A2 were shown to be direct targets of miR-513b-5p in patients with intracranial aneurysms. Downregulation of the index miRNA leads to overexpression of COL1A1
and COL1A2, enhanced MMP activity, abnormal collagen metabolism in the extracellular
matrix (ECM) and possibly aneurysmal rupture. A similar increase in expression of collagen
type I and increased MMP activity has been shown in amniotic membranes of patients with
PPROM even in the absence of inflammation [29]. It is hypothesized that activation of MMPs
in PPROM leads to increased collagen degradation in the amniotic membranes. Studies in rabbits also support that MMPs are involved in matrix remodeling as part of the healing process
of PPROM [30]. Hence, overexpression of collagen type I might be an attempt to restore normal collagen levels in the ECM of fetal membranes. It is unclear whether decreased expression
of miR-513b-5p could be causative to the mechanism leading to membrane rupture or reactive
and part of the healing process.
The elevated levels of miR-119a-5p, miR-130a-3p and miR-26a-5p appear to have an effect
on a large number of genes as shown in Fig 4. However, there is significant overlap of all three
in the regulation of the SMAD signal transduction pathway. The SMAD signal transduction
pathway and TGF-β have been shown to regulate gene expression of type I collagen, COL1A1
and COL1A2 [31, 32].
MiR-516b-5p and miR-526a were downregulated in PPROM patients but did not reach
FDR-adjusted statistical significance. They both belong to the C19MC cluster that is placenta
specific. Hromadnikova et al. [33] also identified decreased expression of the above miRNAs
in the placentas of patients with PPROM. The lack of statistical significance in our study could

Fig 4. miRTargetLink 2.0—Interactive miRNA target gene and target pathway networks.
https://doi.org/10.1371/journal.pone.0277098.g004
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Fig 5. miRWalk GeneOntology database prediction for target miRNAs.
https://doi.org/10.1371/journal.pone.0277098.g005

be the result of sampling maternal serum compared to reproductive tissues such as placenta or
cervix or due to the relatively small sample size.
Several other studies in the literature have reported unique miRNA profiles in the placenta
of patients with PPROM, preterm birth and other pregnancy complications such as preeclampsia and fetal growth restriction [33–35]. Elovitz et al. [36] examined miRNA expression
in cervical cells of patients destined to have preterm birth and identified a distinct profile in
this group. However, maternal serum miRNA signatures in the same group did not yield statistically significant results leading to the conclusion that local miRNA panels targeting reproductive tissues might prove more beneficial for discovering biomarkers or understanding of
disease pathophysiology.
Clinical implications. Our findings shed some light in the pathophysiology underlying
PPROM. ECM remodeling, altered collagen metabolism and increased MMP in fetal membranes have been reported in PPROM [29, 30]. Altered miRNA expression as shown in our
study could be one of the mediators for these effects.
Specimen collection in our study was performed after the diagnosis of PPROM, hence it is
unclear whether the distinct miRNA signature identified can be used as a potential biomarker
for prediction of PPROM in otherwise asymptomatic patients. Nevertheless, the altered
expression of miRNAs and the downstream effects on their putative gene targets are consistent
with known pathways that have been previously implicated in PPROM. Since miRNAs from
reproductive tissues, such as amniotic membranes and the placenta, can be released into the
maternal circulation, it would be anticipated that local differences in expression can be
detected systemically, but likely at lower expression levels than in placenta or cervical tissue.
This release could be enhanced with interruption of the maternal-fetal interface such as in
PPROM.
Research implications. Considering that our tissue sample was maternal serum and not
amniotic membranes it would be important for future research to validate the above miRNA
findings in reproductive tissues. In addition, future research on amniotic membranes could
confirm or refute whether cell transfection with the above miRNAs alters mRNA expression
for COL1A1 and COL1A2 by up- or down-regulation of their respective pathways.
Strengths and limitations. Our study strengths include: 1) all specimens were blinded to
the lab performing the quantification of miRNA levels, 2) patients in the control and PPROM
groups were matched by gestational age, 3) we used an established microarray technology for
quantification of miRNAs, 4) specimen collection for the PPROM group was performed before
the administration of betamethasone and latency antibiotics, thus ruling out any possible effect
on the miRNA expression profile.
Our study was limited by recruiting patients after PPROM was diagnosed, hence not allowing for conclusions regarding the prognostic ability of the miRNA profile in PPROM. However, our primary goal was to elucidate pathways associated with PPROM pathophysiology
rather than the identification of predictive biomarkers. In addition, our study lacked a validation cohort for the differentially expressed miRNAs. Even though the use of the false discovery
rate for statistical significance decreased the likelihood of false-positive and false-negative
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results, other modalities such as qRT-PCR might identify different miRNA expression levels.
We also did not sample miRNAs in reproductive tissues such as amniotic membranes or cervix, that some researchers have proposed as preferable specimens to peripheral blood. Finally,
the number of specimens obtained was limited.

Conclusion
In summary, our findings suggest that patients with PPROM have a distinct serum miRNA
profile compared to controls. Exploring local miRNA expression in reproductive tissues from
patients before and after PPROM is diagnosed will be able to shed more light into its pathophysiology and possibly identify prognostic and therapeutic targets.
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